New Enterprise Associates

ZeroFox, Inc. is a cybersecurity company that specializes in protecting organizations from social media-based threats. Utilizing a cloud-based platform, ZeroFox offers real-time analytics and protection against various cyber threats, including phishing attacks, account takeovers, and impersonation. The company's services include proactive monitoring of social media and digital communication platforms to identify and mitigate risks, safeguarding both brands and high-value individuals like executives from targeted fraud and scams. ZeroFox also provides specific solutions for political campaigns to defend against election-related threats. With a focus on comprehensive threat intelligence, the company employs advanced technology to monitor the surface, deep, and dark web, ensuring businesses can respond effectively to emerging threats. Founded in 2013 and headquartered in Baltimore, Maryland, ZeroFox has additional offices in London, Chile, and India, serving clients across diverse sectors such as finance, healthcare, and education.

IonQ, Inc. specializes in the development of general-purpose quantum information computers, utilizing a trapped ion approach that allows for qubit replication and optimized algorithms. Founded in 2015 and headquartered in College Park, Maryland, the company aims to overcome the limitations of classical computing by harnessing the principles of superposition and entanglement at the atomic scale. IonQ offers access to its quantum computers with varying qubit capacities, primarily through cloud platforms, making quantum computing available as a service. In addition to its cloud offerings, the company generates revenue from consulting services that involve co-developing algorithms tailored for its quantum systems. IonQ is actively engaged in research and development to enhance the computational capabilities of its quantum technologies.

Personal Genome Diagnostics, Inc. specializes in patient-specific cancer genome analysis using advanced digital characterization and monitoring technologies. Founded in 2010 and based in Baltimore, Maryland, the company offers a range of products and services aimed at improving cancer diagnosis and treatment. Their METDetect Assay detects MET gene amplifications in cancer patients' circulation, providing detailed reports on tumor-specific alterations. The LungSelect product identifies actionable genetic changes in plasma from non-small cell lung cancer patients, while PGDx elio plasma resolve is a diagnostic test that detects various genetic alterations in circulating cell-free DNA. Additionally, the company offers RNAcomplete, which allows for the extraction of total RNA and genomic DNA from single tissue samples, and CancerXOME, which analyzes the coding regions of numerous genes. Personal Genome Diagnostics collaborates with institutions like Mayo Clinic and has partnerships with KingMed Diagnostics to further enhance cancer genome research and diagnostics.

ZeroFox, Inc. is a cybersecurity company that specializes in protecting organizations from social media-based threats. Utilizing a cloud-based platform, ZeroFox offers real-time analytics and protection against various cyber threats, including phishing attacks, account takeovers, and impersonation. The company's services include proactive monitoring of social media and digital communication platforms to identify and mitigate risks, safeguarding both brands and high-value individuals like executives from targeted fraud and scams. ZeroFox also provides specific solutions for political campaigns to defend against election-related threats. With a focus on comprehensive threat intelligence, the company employs advanced technology to monitor the surface, deep, and dark web, ensuring businesses can respond effectively to emerging threats. Founded in 2013 and headquartered in Baltimore, Maryland, ZeroFox has additional offices in London, Chile, and India, serving clients across diverse sectors such as finance, healthcare, and education.

IonQ, Inc. specializes in the development of general-purpose quantum information computers, utilizing a trapped ion approach that allows for qubit replication and optimized algorithms. Founded in 2015 and headquartered in College Park, Maryland, the company aims to overcome the limitations of classical computing by harnessing the principles of superposition and entanglement at the atomic scale. IonQ offers access to its quantum computers with varying qubit capacities, primarily through cloud platforms, making quantum computing available as a service. In addition to its cloud offerings, the company generates revenue from consulting services that involve co-developing algorithms tailored for its quantum systems. IonQ is actively engaged in research and development to enhance the computational capabilities of its quantum technologies.

Personal Genome Diagnostics, Inc. specializes in patient-specific cancer genome analysis using advanced digital characterization and monitoring technologies. Founded in 2010 and based in Baltimore, Maryland, the company offers a range of products and services aimed at improving cancer diagnosis and treatment. Their METDetect Assay detects MET gene amplifications in cancer patients' circulation, providing detailed reports on tumor-specific alterations. The LungSelect product identifies actionable genetic changes in plasma from non-small cell lung cancer patients, while PGDx elio plasma resolve is a diagnostic test that detects various genetic alterations in circulating cell-free DNA. Additionally, the company offers RNAcomplete, which allows for the extraction of total RNA and genomic DNA from single tissue samples, and CancerXOME, which analyzes the coding regions of numerous genes. Personal Genome Diagnostics collaborates with institutions like Mayo Clinic and has partnerships with KingMed Diagnostics to further enhance cancer genome research and diagnostics.

Senseonics Holdings, Inc. is a medical technology company based in Germantown, Maryland, specializing in continuous glucose monitoring (CGM) systems for individuals with diabetes. Founded in 1996, the company focuses on developing innovative implantable CGM products, including the Eversense and Eversense XL systems, which measure glucose levels for up to 90 and 180 days, respectively. These systems utilize advanced fluorescence sensing technology to provide accurate and stable glucose monitoring, allowing users to manage their diabetes effectively. Senseonics primarily generates revenue from markets outside the United States, highlighting its commitment to enhancing the lives of people with diabetes through long-term, differentiated glucose management solutions.

Vtesse, Inc. is a biopharmaceutical company based in Gaithersburg, Maryland, focused on developing treatments for patients with rare diseases. The company is conducting clinical studies for VTS-270, aimed at treating Niemann-Pick disease type C (NPC), and is also engaged in pre-clinical discovery and development of additional therapies for NPC and other lysosomal storage diseases. Vtesse originated as the first spin-out from Cydan Development, an orphan-drug accelerator that identifies promising therapeutic programs. The company collaborates with the National Institutes of Health (NIH) to advance its clinical studies and is supported by a consortium of experienced investors. Vtesse's management team has a strong background, having participated in the development of over 20 approved drugs and vaccines, which underscores its commitment to addressing the needs of underserved patient populations.

ZeroFox, Inc. is a cybersecurity company that specializes in protecting organizations from social media-based threats. Utilizing a cloud-based platform, ZeroFox offers real-time analytics and protection against various cyber threats, including phishing attacks, account takeovers, and impersonation. The company's services include proactive monitoring of social media and digital communication platforms to identify and mitigate risks, safeguarding both brands and high-value individuals like executives from targeted fraud and scams. ZeroFox also provides specific solutions for political campaigns to defend against election-related threats. With a focus on comprehensive threat intelligence, the company employs advanced technology to monitor the surface, deep, and dark web, ensuring businesses can respond effectively to emerging threats. Founded in 2013 and headquartered in Baltimore, Maryland, ZeroFox has additional offices in London, Chile, and India, serving clients across diverse sectors such as finance, healthcare, and education.

Personal Genome Diagnostics, Inc. specializes in patient-specific cancer genome analysis using advanced digital characterization and monitoring technologies. Founded in 2010 and based in Baltimore, Maryland, the company offers a range of products and services aimed at improving cancer diagnosis and treatment. Their METDetect Assay detects MET gene amplifications in cancer patients' circulation, providing detailed reports on tumor-specific alterations. The LungSelect product identifies actionable genetic changes in plasma from non-small cell lung cancer patients, while PGDx elio plasma resolve is a diagnostic test that detects various genetic alterations in circulating cell-free DNA. Additionally, the company offers RNAcomplete, which allows for the extraction of total RNA and genomic DNA from single tissue samples, and CancerXOME, which analyzes the coding regions of numerous genes. Personal Genome Diagnostics collaborates with institutions like Mayo Clinic and has partnerships with KingMed Diagnostics to further enhance cancer genome research and diagnostics.

Vtesse, Inc. is a biopharmaceutical company based in Gaithersburg, Maryland, focused on developing treatments for patients with rare diseases. The company is conducting clinical studies for VTS-270, aimed at treating Niemann-Pick disease type C (NPC), and is also engaged in pre-clinical discovery and development of additional therapies for NPC and other lysosomal storage diseases. Vtesse originated as the first spin-out from Cydan Development, an orphan-drug accelerator that identifies promising therapeutic programs. The company collaborates with the National Institutes of Health (NIH) to advance its clinical studies and is supported by a consortium of experienced investors. Vtesse's management team has a strong background, having participated in the development of over 20 approved drugs and vaccines, which underscores its commitment to addressing the needs of underserved patient populations.

D2L Corporation is a learning innovation company founded in 1999 and headquartered in Kitchener, Canada, with additional locations in Toronto, Winnipeg, Maryland, Australia, and the United Kingdom. The company specializes in providing cloud-based learning solutions through its platform, Brightspace, which serves a diverse range of clients, including higher education institutions, K-12 schools, healthcare organizations, government agencies, and enterprise sectors. Brightspace combines usability, integrated analytics, and accessibility to enhance the learning experience, offering tools such as course recommendations, adaptive learning, online grading, and mobile applications that facilitate student engagement. D2L aims to inspire lifelong learning by delivering high-quality educational experiences to over 700 clients and more than 8 million learners globally.

Cerecor Inc. is a biopharmaceutical company dedicated to the development and commercialization of treatments for rare pediatric and orphan diseases. Founded in 2011 and headquartered in Rockville, Maryland, the company is advancing a clinical-stage pipeline that includes therapies for inherited metabolic disorders, such as CERC-801, CERC-802, and CERC-803, which are focused on congenital disorders of glycosylation. Additionally, Cerecor is developing CERC-006, an oral mTOR inhibitor aimed at treating complex lymphatic malformations, and two monoclonal antibodies: CERC-002, targeting the cytokine LIGHT for severe pediatric-onset Crohn's disease, and CERC-007, targeting IL-18 for autoimmune inflammatory diseases like adult onset Still's disease and multiple myeloma. Several of these therapies have received Orphan Drug Designation and Rare Pediatric Disease Designation, qualifying them for expedited review upon FDA approval. Cerecor also offers Millipred, an oral prednisolone for various inflammatory conditions.

NexImmune, Inc. is a clinical-stage biopharmaceutical company based in Gaithersburg, Maryland, specializing in the development of innovative immuno-therapeutics utilizing its proprietary Artificial Immune (AIM) technology. This technology is designed to enhance the immune system's ability to generate specific responses to targeted antigens, which is crucial for effective cancer treatment and other immune-mediated diseases. NexImmune's product offerings include AIM101, an injectable therapy for certain solid tumors, and AIM ACT, an adoptive cellular therapy aimed at treating specific hematological malignancies. The company is currently advancing two product candidates in human trials: NEXI-001 for acute myeloid leukemia and NEXI-002 for multiple myeloma. By focusing on improving the body's T cell responses, NexImmune aims to provide curative therapies for patients facing life-threatening conditions.

Senseonics Holdings, Inc. is a medical technology company based in Germantown, Maryland, specializing in continuous glucose monitoring (CGM) systems for individuals with diabetes. Founded in 1996, the company focuses on developing innovative implantable CGM products, including the Eversense and Eversense XL systems, which measure glucose levels for up to 90 and 180 days, respectively. These systems utilize advanced fluorescence sensing technology to provide accurate and stable glucose monitoring, allowing users to manage their diabetes effectively. Senseonics primarily generates revenue from markets outside the United States, highlighting its commitment to enhancing the lives of people with diabetes through long-term, differentiated glucose management solutions.

ZeroFox, Inc. is a cybersecurity company that specializes in protecting organizations from social media-based threats. Utilizing a cloud-based platform, ZeroFox offers real-time analytics and protection against various cyber threats, including phishing attacks, account takeovers, and impersonation. The company's services include proactive monitoring of social media and digital communication platforms to identify and mitigate risks, safeguarding both brands and high-value individuals like executives from targeted fraud and scams. ZeroFox also provides specific solutions for political campaigns to defend against election-related threats. With a focus on comprehensive threat intelligence, the company employs advanced technology to monitor the surface, deep, and dark web, ensuring businesses can respond effectively to emerging threats. Founded in 2013 and headquartered in Baltimore, Maryland, ZeroFox has additional offices in London, Chile, and India, serving clients across diverse sectors such as finance, healthcare, and education.

Bravo Health, Inc. is a managed care provider that specializes in offering Medicare Advantage plans, including options tailored for special needs populations such as those receiving institutional care or individuals with chronic health conditions. The company also provides private fee-for-service plans, allowing members the flexibility to choose their healthcare providers, as well as Part D prescription drug plans for those requiring medication coverage. Bravo Health serves members across several states, including Delaware, Maryland, Pennsylvania, Texas, New Jersey, and Washington, D.C., and extends its prescription drug plans to 43 states. Founded in 1996 and based in Baltimore, Maryland, the company was formerly known as Elder Health, Inc.

D2L Corporation is a learning innovation company founded in 1999 and headquartered in Kitchener, Canada, with additional locations in Toronto, Winnipeg, Maryland, Australia, and the United Kingdom. The company specializes in providing cloud-based learning solutions through its platform, Brightspace, which serves a diverse range of clients, including higher education institutions, K-12 schools, healthcare organizations, government agencies, and enterprise sectors. Brightspace combines usability, integrated analytics, and accessibility to enhance the learning experience, offering tools such as course recommendations, adaptive learning, online grading, and mobile applications that facilitate student engagement. D2L aims to inspire lifelong learning by delivering high-quality educational experiences to over 700 clients and more than 8 million learners globally.

Sonatype, Inc. specializes in software supply chain automation, providing solutions that enable organizations to effectively manage their development lifecycles, including third-party and first-party code, infrastructure as code, and containerized applications. The company's flagship products include Nexus Lifecycle, which governs the flow of software components and enforces policies; Nexus Firewall, which prevents risky components from entering the supply chain; Nexus Auditor, for continuous monitoring of applications in production; and Nexus Repository, which organizes and distributes software components. Sonatype serves diverse industries such as finance, government, technology, insurance, healthcare, and manufacturing, supporting a significant portion of Fortune 100 companies. Established in 2008 and headquartered in Fulton, Maryland, the company also has offices in McLean, Virginia; London, United Kingdom; and Sydney, Australia. Sonatype is recognized for its commitment to innovation and has received accolades for its workplace culture and growth.

Millennial Media Inc. is a prominent provider of mobile advertising solutions, catering to advertisers and developers in the United States and internationally. Founded in 2006 and headquartered in Baltimore, Maryland, the company offers a range of services that enable advertisers to effectively reach and engage their target audiences across various mobile devices. Its offerings include a demand-side platform for direct inventory access, a premium mobile advertising exchange, and tools for designing advertisements. Millennial Media also supports developers with software development kits for various ad formats, ad serving capabilities, and mediation tools that optimize ad requests from multiple sources. Additionally, the company operates MYDAS, a mobile advertising technology that identifies unique users and tailors ad delivery based on interests and behaviors. Millennial Media serves a significant portion of leading advertisers and is recognized for providing an attractive monetization platform for app developers and publishers.

Millennial Media Inc. is a prominent provider of mobile advertising solutions, catering to advertisers and developers in the United States and internationally. Founded in 2006 and headquartered in Baltimore, Maryland, the company offers a range of services that enable advertisers to effectively reach and engage their target audiences across various mobile devices. Its offerings include a demand-side platform for direct inventory access, a premium mobile advertising exchange, and tools for designing advertisements. Millennial Media also supports developers with software development kits for various ad formats, ad serving capabilities, and mediation tools that optimize ad requests from multiple sources. Additionally, the company operates MYDAS, a mobile advertising technology that identifies unique users and tailors ad delivery based on interests and behaviors. Millennial Media serves a significant portion of leading advertisers and is recognized for providing an attractive monetization platform for app developers and publishers.

Optinuity, Inc. specializes in autonomic policy management solutions aimed at enterprises and service providers. The company's flagship product, Optinuity Oasis, enables organizations to create and implement autonomic policies that facilitate self-management of complex business systems. In addition to its software offerings, Optinuity provides a range of professional services, including autonomic policy planning and design, installation and configuration, custom development, and training. The company's solutions are particularly tailored for the financial services, healthcare, and telecommunications sectors. Founded in 2004 and headquartered in Bethesda, Maryland, Optinuity operates as a subsidiary of CA, Inc.

Hillcrest Laboratories is a prominent global supplier of motion processing solutions that utilize MEMS sensors to capture and interpret human and mechanical movement. These advanced technologies enable interaction with various devices and enhance products across consumer technology and industrial sectors. The company is well-known for its contributions to the Smart TV market, having developed HoME, the first pointer-based interactive media system, and the award-winning Loop remote control. Its client base includes notable names such as LG, Roku, and TCL. In addition to its Smart TV roots, Hillcrest has broadened its focus to serve the smartphone and mobile device industries, license technology to leading gaming systems, and provide solutions for virtual reality applications. The company has garnered multiple awards, including several CES Innovations Awards and recognition from PC World and Popular Mechanics. Founded in 2001 in Rockville, Maryland, by Dan Simpkins, Hillcrest Labs is supported by investors such as NEA, Columbia Capital, and Grotech Capital.

GlycoMimetics, Inc., a biopharmaceutical company, engages in the design and development of small molecule therapeutics to mimic the functions of bioactive carbohydrates. Its products include GMI-1070, a synthetic glycomimetic molecule designed to inhibit selectin types, such as E, P, and L-selectin; and GMI-1051, a small molecular weight compound for the treatment or prevention of infections caused by pseudomonas aeruginosa. The company was founded in 2003 and is based in Gaithersburg, Maryland. GlycoMimetics, Inc. acquired by Crescent BioPharma in an Reverse Merger, where GlycoMimetics changed its name to Crescent BioPharma, Inc.

Sourcefire, Inc. specializes in enterprise threat management solutions for various sectors, including healthcare, finance, manufacturing, energy, education, retail, telecommunications, and government organizations, both in the United States and internationally. The company develops a range of open-source and commercial security products, notably Snort, which is an open-source intrusion prevention technology integrated into its Sourcefire 3D System. This system combines multiple hardware and software offerings to provide a comprehensive network defense that includes intrusion prevention, network behavior analysis, network access control, and vulnerability assessment. Additionally, Sourcefire offers ClamAV, an open-source anti-virus and anti-malware solution. The company also provides technical support and professional services, such as network security deployment and customer education. Sourcefire's products are marketed through direct sales and a network of resellers, distributors, and original equipment manufacturers. Founded in 2001, the company is headquartered in Columbia, Maryland.

Optinuity, Inc. specializes in autonomic policy management solutions aimed at enterprises and service providers. The company's flagship product, Optinuity Oasis, enables organizations to create and implement autonomic policies that facilitate self-management of complex business systems. In addition to its software offerings, Optinuity provides a range of professional services, including autonomic policy planning and design, installation and configuration, custom development, and training. The company's solutions are particularly tailored for the financial services, healthcare, and telecommunications sectors. Founded in 2004 and headquartered in Bethesda, Maryland, Optinuity operates as a subsidiary of CA, Inc.

GlycoMimetics, Inc., a biopharmaceutical company, engages in the design and development of small molecule therapeutics to mimic the functions of bioactive carbohydrates. Its products include GMI-1070, a synthetic glycomimetic molecule designed to inhibit selectin types, such as E, P, and L-selectin; and GMI-1051, a small molecular weight compound for the treatment or prevention of infections caused by pseudomonas aeruginosa. The company was founded in 2003 and is based in Gaithersburg, Maryland. GlycoMimetics, Inc. acquired by Crescent BioPharma in an Reverse Merger, where GlycoMimetics changed its name to Crescent BioPharma, Inc.

Psyadon Pharmaceuticals, Inc. is engaged in the discovery and development of innovative drugs aimed at addressing psychiatric and neurological diseases. Founded in 2004 and based in Germantown, Maryland, the company specializes in Ecopipam, a drug that selectively blocks the actions of the neurotransmitter dopamine at the D1 subtype in the brain. This therapeutic approach is designed to provide treatment options for patients suffering from serious conditions who have limited alternatives. Formerly known as Ruxton Pharmaceuticals, Inc., the company changed its name in October 2008 and currently operates as a subsidiary of Emalex Biosciences, Inc. Psyadon Pharmaceuticals is committed to advancing medical solutions that can significantly benefit individuals with challenging health issues.

Sourcefire, Inc. specializes in enterprise threat management solutions for various sectors, including healthcare, finance, manufacturing, energy, education, retail, telecommunications, and government organizations, both in the United States and internationally. The company develops a range of open-source and commercial security products, notably Snort, which is an open-source intrusion prevention technology integrated into its Sourcefire 3D System. This system combines multiple hardware and software offerings to provide a comprehensive network defense that includes intrusion prevention, network behavior analysis, network access control, and vulnerability assessment. Additionally, Sourcefire offers ClamAV, an open-source anti-virus and anti-malware solution. The company also provides technical support and professional services, such as network security deployment and customer education. Sourcefire's products are marketed through direct sales and a network of resellers, distributors, and original equipment manufacturers. Founded in 2001, the company is headquartered in Columbia, Maryland.

Hillcrest Laboratories is a prominent global supplier of motion processing solutions that utilize MEMS sensors to capture and interpret human and mechanical movement. These advanced technologies enable interaction with various devices and enhance products across consumer technology and industrial sectors. The company is well-known for its contributions to the Smart TV market, having developed HoME, the first pointer-based interactive media system, and the award-winning Loop remote control. Its client base includes notable names such as LG, Roku, and TCL. In addition to its Smart TV roots, Hillcrest has broadened its focus to serve the smartphone and mobile device industries, license technology to leading gaming systems, and provide solutions for virtual reality applications. The company has garnered multiple awards, including several CES Innovations Awards and recognition from PC World and Popular Mechanics. Founded in 2001 in Rockville, Maryland, by Dan Simpkins, Hillcrest Labs is supported by investors such as NEA, Columbia Capital, and Grotech Capital.

GlycoMimetics, Inc., a biopharmaceutical company, engages in the design and development of small molecule therapeutics to mimic the functions of bioactive carbohydrates. Its products include GMI-1070, a synthetic glycomimetic molecule designed to inhibit selectin types, such as E, P, and L-selectin; and GMI-1051, a small molecular weight compound for the treatment or prevention of infections caused by pseudomonas aeruginosa. The company was founded in 2003 and is based in Gaithersburg, Maryland. GlycoMimetics, Inc. acquired by Crescent BioPharma in an Reverse Merger, where GlycoMimetics changed its name to Crescent BioPharma, Inc.

Iomai Corporation specializes in the discovery and development of vaccines and immune system stimulants using a unique, needle-free approach known as transcutaneous immunization (TCI). This technology utilizes antigen-presenting cells located in the outer layers of the skin to enhance immune responses, allowing for the improvement of existing vaccines and the creation of new ones that can only be administered through this method. Founded in 1997 and based in Gaithersburg, Maryland, Iomai aims to expand the global vaccine market. Following its acquisition by Intercell Ag, the company was rebranded as Intercell USA, Inc. and now operates as a subsidiary of Intercell Biomedical Research & Development AG.